Pulmonary delivery of deslorelin: Large-porous PLGA particles and HPβCD complexes

Pharmaceutical Research

Volumn 21, Issue 7, 2004, Pages 1119-1126

  Koushik, Kavitha ^a   Dhanda, Devender S ^a   Cheruvu, Narayan P S ^a   Kompella, Uday B ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

deslorelin; HP CD; intratracheal; large porous particles; PLGA.

Indexed keywords

BETA CYCLODEXTRIN DERIVATIVE; DESLORELIN; DESLORELIN HYDROXYPROPYL BETA CYCLODEXTRIN COMPLEX; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DENSITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; ENZYME IMMUNOASSAY; INFORMATION PROCESSING; LUNG LAVAGE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN;

ADMINISTRATION, INHALATION; ANIMALS; BETA-CYCLODEXTRINS; BRONCHOALVEOLAR LAVAGE FLUID; DRUG CARRIERS; LACTIC ACID; LUNG; MALE; PARTICLE SIZE; PHARMACEUTICAL SOLUTIONS; POLYGLYCOLIC ACID; POLYMERS; POROSITY; POWDERS; RATS; RATS, SPRAGUE-DAWLEY; TRACHEA; TRIPTORELIN;

EID: 3242669006     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000032997.96823.88     Document Type: Article

References (42)

1. D. A. Groneberg, C. Witt, U. Wagner, K. F. Chung, and A. Fischer. Fundamentals of pulmonary drug delivery. Respir. Med. 97:382-387 (2003).
2. D. A. Edwards and C. Dunbar. Bioengineering of therapeutic aerosols. Annu. Rev. Biomed. Eng. 4:93-107 (2002).
3. R. U. Agu, M. I. Ugwoke, M. Armand, R. Kinget, and N. Verbeke. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2:198-209 (2001).
4. W. Vale, C. Rivier, M. Brown, and J. Rivier. Clinical Endocrinology, 5th Supplement, Blackwell Scientific Publications, Oxford, 1976.
5. A. V. Schally. LH-RH analogues: I. Their impact on reproductive medicine. Gynecol. Endocrinol. 13:401-409 (1999).
6. R. U. Agu, M. I. Ugwoke, M. Armand, R. Kinget, and N. Verbeke. The lung as a route for the systemic delivery of therapeutic proteins and peptides. Respir. Res. 2:198-209 (2001).
7. A. Adjeiand and P. K. Gupta. Inhalation Delivery of Therapeutic Peptides and Proteins, Marcel Dekker, New York, 1997.
8. K. Koushik, G. Sunkara, P. Gwilt, and U. B. Kompella. Pathways and kinetics of deslorelin degradation in an airway epithelial cell line (Calu-1). Pharm. Res. 20:779-787 (2003).
9. J. Pitha. Amorphous water-soluble derivatives of cyclodextrins: nontoxic dissolution enhancing excipients. J. Pharm. Sci. 74:987-990 (1985).
10. K. N. Koushik, N. Bandi, and U. B. Kompella. Interaction of [D-Trp6, Des-Gly10] LHRH ethylamide and hydroxy propyl beta-cyclodextrin (HPβCD): thermodynamics of interaction and protection from degradation by alpha-chymotrypsin. Pharm. Dev. Technol. 6:595-606 (2001).
11. J. G. Hardy and T. S. Chadwick. Sustained release drug delivery to the lungs: an option for the future. Clin. Pharmacokinet. 39:1-4 (2000).
12. J. Jones. Clearance of inhaled particles from the alveoli. In S. W. Clarke (ed.), Aerosol and the Lung: Clinical and Experimental Aspects, Butterworth, London, 1984.
13. D. A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M. L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer. Large porous particles for pulmonary drug delivery. Science 276:1868-1871 (1997).
14. K. Koushik and U. B. Kompella. Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent content and cellular uptake using a supercritical CO2 process. Pharm. Res. (2004).
15. U. B. Kompella and K. Koushik. Preparation of drug delivery systems using supercritical fluid technology. Crit. Rev. Ther. Drug Carrier Syst. 18:173-199 (2001).
16. M. A. McHugh and V. J. Krukonis. Supercritical Fluid Extraction: Principles and Practice, Butterworth-Heinemann, Newton, 1994.
17. R. Alcock, J. A. Blair, D. J. O'Mahony, A. Raoof, and A. V. Quirk. Modifying the release of leuprolide from spray dried OED microparticles. J. Control. Rel. 82:429-440 (2002).
18. L. Garcia-Contreras, T. Morcol, S. J. Bell, and A. J. Hickey. Evaluation of novel particles as pulmonary delivery systems for insulin in rats. AAPS PharmSci. 5:E9 (2003).
19. S. Sanjar. and J. Matthews. Treating systemic diseases via the lung. J. Aerosol Med. 14:S51-S58 (2001).
20. K. Matsubara, K. Abe, T. Irie, and K. Uekama. Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats. J. Pharm. Sci. 84:1295-1300 (1995).
21. T. Nakate, H. Yoshida, A. Ohike, Y. Tokunaga, R. Ibuki, and Y. Kawashima. Comparison of the lung absorption of FK224 inhaled from a pressurized metered dose inhaler and a dry powder inhaler by healthy volunteers. Eur. J. Pharm. Biopharm. 56:319-325 (2003).
22. S. Kobayashi, S. Kondo, and K. Juni. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm. Res. 13:80-83 (1996).
23. A. Hussain, J. J. Arnold, M. A. Khan, and F. Ahsan. Absorption enhancers in pulmonary protein delivery. J. Controll. Rel. 94:15-24 (2004).
24. T. Irie, K. Fukunaga, and J. Pitha. Hydroxypropylcyclodextrins in parenteral use. I: lipid dissolution and effects on lipid transfers in vitro. J. Pharm. Sci. 81:521-523 (1992).
25. Z. Shao, R. Krishnamoorthy, and A. K. Mitra. Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations. Pharm. Res. 9:1157-1163 (1992).
26. T. Irie and K. Uekama. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86:147-162 (1997).
27. J. W. Kostanski and P. P. DeLuca. A novel in vitro release technique for peptide containing biodegradable microspheres. AAPS PharmSciTech 1:E4 (2000).
28. H. Okada, T. Heya, Y. Ogawa, and T. Shimamoto. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. J. Pharmacol. Exp. Ther. 244:744-750 (1988).
29. M. S. Shive and J. M. Anderson. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28:5-24 (1997).
30. G. Oberdorster, M. J. Utell, P. E. Morrow, R. W. Hyde, and D. A. Weber. Bronchial and alveolar absorption of inhaled 99mTc-DTPA. Am. Rev. Respir. Dis. 134:944-950 (1986).
31. W. Moller, W. Earth, M. Kohlhaufl, K. Haussinger, and W. Stahlhofen. and J. Heyder. Human alveolar long-term clearance of ferromagnetic iron oxide microparticles in healthy and diseased subjects. Exp. Lung Res. 27:547-568 (2001).
32. T. M. Crowder, J. A. Rosati, J. D. Schroeter, A. J. Hickey, and T. B. Martonen. Fundamental effects of particle morphology on lung delivery: predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm. Res. 19:239-245 (2002).
33. C. J. Musante, J. D. Schroeter, J. A. Rosati, T. M. Crowder, A. J. Hickey, and T. B. Martonen. Factors affecting the deposition of inhaled porous drug particles. J. Pharm. Sci. 91:1590-1600 (2002).
34. C. Dunbar, G. Scheuch, K. Sommerer, M. DeLong, A. Verma, and R. Batycky. In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. Int. J. Pharm. 245:179-189 (2002).
35. D. A. Edwards and W. Li. Aerosol particle transport and deaggregation phenomena in the mouth and throat. Adv. Drug Deliv. Rev. 26:41-49 (1997).
36. S. P. Duddu, S. A. Sisk, Y. H. Walter, T. E. Tarara, K. R. Trimble, A. R. Clark, M. A. Eldon, R. C. Elton, M. Pickford, P. H. Hirst, S. P. Newman, and J. G. Weers. Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder. Pharm. Res. 19:689-695 (2002).
37. T. A. Out, E. A. van de Graaf, and H. M. Jansen. Permeability or local production of immunoglobulins and other inflammatory proteins in asthma. Eur. Respir. J. Suppl. 13:148s-155s (1991).
38. K. Koushik, N. Bandi, S. Sundaram, and U. B. Kompella. Evidence for LHRH-Receptor Expression in Human Airway Epithelial (Calu-3) Cells and its Role in the Transport of an LHRH Agonist. Pharm. Res. 21:1040-1052 (2004).
39. A. Ben-Jebria, D. Chen, M. L. Eskew, R. Vanbever, R. Langer, and D. A. Edwards. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm. Res. 16:555-561 (1999).
40. J. Wang, A. Ben-Jebria, and D. A. Edwards. Inhalation of estradiol for sustained systemic delivery. J. Aerosol Med. 12:27-36 (1999).
41. S. Suarez, P. O'Hara, M. Kazanlseva, C. E. Newcomer, R. Hopfer, D. N. McMurray, and A. J. Hickey. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J. Antimicrob. Chemother. 48:431-434 (2001).
42. A. Diaz and M. Danon. Recent advances in the diagnosis and treatment of precocious puberty. Indian J. Pediatr. 67:211-215 (2000).